Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can stem cells help heal a broken heart? new study investigates

NCT ID NCT07604467

Knowledge-focused Sponsor: University Medical Centre Ljubljana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether CD34+ stem cells, which help maintain tiny blood vessels in the heart, are linked to how well the heart recovers in people with Takotsubo syndrome (also known as broken heart syndrome). Researchers will measure heart function in 40 participants at the start and after 6 months. The goal is to better understand the role of these stem cells in heart recovery, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CD34+ stem cells
What this could lead to
If successful, this could point toward a way to predict or improve heart recovery in people with Takotsubo syndrome.
What could go wrong
This is a small, early observational study, not a treatment trial. It may not lead to any new therapy, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients, predominantly females, with cardiovascular risk factors.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Minimum age 18 years * Established TTS per InterTak registry criteria * Signed consent form Exclusion Criteria: * Patients under the age of 18 years * Ischemic heart disease with at least one complete total occlusion * Other concurrent cardiomyopathies * Active infectious myocarditis * obstructive coronary artery disease * Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event * Previous interventional coronary artery procedure in the last 6 months before TTS acute event * Significant valvular heart disease * Significant peripheral artery occlusive disease * Active or remitted hematologic malignancy * Patients receiving immunosuppressive therapy * Significant comorbiditeis affecting patients survival (malignancy) * Failure to obtain freely given, informed consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac contractility recovery are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary microvascular disorder heart failure Tako-tsubo cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac contractility recovery CD34+ stem cells Heart failure Microvascular dysfunction Tako tsubo cardiomyopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Advanced Heart Failure and Transplantation Program, Department of Cardiology, UMC Ljubljana, Slovenia

    RECRUITING

    Ljubljana, Ljubljana, 1000, Slovenia

More trials for these conditions

Other studies related to the condition(s) this trial covers.